Tirzepatide wins. Here's by how much.
The 2025 SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine ended a three-year debate: tirzepatide vs semaglutide at maximum doses produced 20.2% body weight loss for tirzepatide (Zepbound) compared to 13.7% for semaglutide (Wegovy) over 72 weeks. That's 47% more weight lost on tirzepatide. Both drugs work. One works substantially better.
This page covers the full tirzepatide vs semaglutide comparison: SURMOUNT-5 trial data, mechanism (single GLP-1 vs dual GLP-1/GIP), side effects, cost, insurance, dosing, switching protocols, and which one fits your specific situation.
🔑 Key Takeaways
- Tirzepatide vs semaglutide head-to-head: 20.2% body weight loss with tirzepatide (Zepbound 15mg) vs 13.7% with semaglutide (Wegovy 2.4mg) at 72 weeks (SURMOUNT-5, NEJM 2025).
- Mechanism: tirzepatide hits two receptors (GLP-1 and GIP), semaglutide hits one (GLP-1 only). The dual action is why tirzepatide outperforms.
- Side effects: nearly identical for both. Nausea, diarrhea, constipation, fatigue. Rates are slightly higher on tirzepatide because the dose response is stronger.
- Cost: brand Zepbound ~$1,060/mo, Wegovy ~$1,350/mo cash. Both can drop to $25 to $200/mo with insurance + savings card.
- Compounded route (cash-pay): compounded tirzepatide $258/mo, compounded semaglutide $146/mo via telehealth. Cheapest legitimate way to access either drug.
- Who picks semaglutide anyway: patients with strong cardiovascular indication (SELECT trial proved Wegovy reduces MACE), pregnancy planning concerns, or insurance-only coverage of Wegovy.
The SURMOUNT-5 Head-to-Head Trial: Tirzepatide vs Semaglutide
For three years, anyone comparing tirzepatide vs semaglutide had to extrapolate from separate trials. SURMOUNT-1 showed Zepbound at 22.5%. STEP-1 showed Wegovy at 14.9%. Different populations, different baselines, different durations. Not a fair comparison.
SURMOUNT-5 fixed that. Published in the New England Journal of Medicine in May 2025 (Aronne et al.), it randomized 751 adults with obesity (no diabetes) to either Zepbound 15mg weekly or Wegovy 2.4mg weekly for 72 weeks. Both arms received identical lifestyle counseling. Mean baseline weight: 113 kg.
| Endpoint at week 72 | Tirzepatide (Zepbound) | Semaglutide (Wegovy) | Difference |
|---|---|---|---|
| Mean body weight loss | 20.2% | 13.7% | +6.5 percentage points |
| Lost ≥15% body weight | 64.6% | 40.1% | +24.5 |
| Lost ≥25% body weight | 31.6% | 16.1% | +15.5 |
| Waist circumference reduction | −18.4 cm | −13.0 cm | +5.4 cm |
| Discontinuation for side effects | 6.1% | 8.0% | tirz slightly better |
The result is decisive. In a like-for-like tirzepatide vs semaglutide comparison at maximum doses, tirzepatide produces approximately 50% more weight loss with comparable tolerability. The probability difference at every weight-loss threshold (≥5%, ≥10%, ≥15%, ≥20%, ≥25%) favored tirzepatide.
How They Work: The Mechanism Difference
The reason tirzepatide vs semaglutide produces such different outcomes is in the molecule. Both drugs activate GLP-1 receptors, which suppress appetite, slow gastric emptying, stimulate insulin release, and signal satiety in the hypothalamus. Semaglutide stops there.
Tirzepatide also activates a second receptor: GIP (glucose-dependent insulinotropic polypeptide). GIP works alongside GLP-1 to enhance insulin sensitivity, modulate fat metabolism, and (theoretically) reduce some of the gastrointestinal side effects seen with pure GLP-1 agonism. Earlier research had suggested GIP might promote obesity, but Eli Lilly's discovery that combining GIP and GLP-1 actually amplifies weight loss was the breakthrough that made tirzepatide possible.
Why dual beats single in tirzepatide vs semaglutide
Receptor saturation. Pushing semaglutide doses higher doesn't proportionally increase weight loss because the GLP-1 receptor is already saturated. Adding GIP receptor activation opens a second metabolic lane, which is why tirzepatide outperforms semaglutide even at lower-than-max doses (SURPASS-2 head-to-head in T2D showed similar tirzepatide superiority).
Tirzepatide vs Semaglutide: Brand Names
This trips up almost every new patient. Both molecules have multiple brand names depending on the indication.
| Drug | Brand | Manufacturer | FDA Indication | Max Weekly Dose |
|---|---|---|---|---|
| Tirzepatide | Zepbound | Eli Lilly | Chronic weight management (obesity) | 15 mg |
| Tirzepatide | Mounjaro | Eli Lilly | Type 2 diabetes | 15 mg |
| Semaglutide | Wegovy | Novo Nordisk | Chronic weight management (obesity) | 2.4 mg |
| Semaglutide | Ozempic | Novo Nordisk | Type 2 diabetes | 2.0 mg |
| Semaglutide | Rybelsus | Novo Nordisk | Type 2 diabetes (oral pill) | 14 mg daily |
Mounjaro and Zepbound are the same molecule; Ozempic and Wegovy are the same molecule. The FDA created different brand names because the obesity indication required separate trial data. For tirzepatide vs semaglutide weight-loss comparisons, Zepbound and Wegovy are the apples-to-apples pair.
Tirzepatide vs Semaglutide: Side Effects
This is the most over-discussed part of the tirzepatide vs semaglutide debate. Side effect profiles are nearly identical. Both are GLP-1 agonists, both slow gastric emptying, both produce the standard GI cluster.
| Side Effect | Tirzepatide (SURMOUNT-1) | Semaglutide (STEP-1) |
|---|---|---|
| Nausea | 29-33% | 44% |
| Diarrhea | 21-23% | 30% |
| Constipation | 17% | 24% |
| Vomiting | 10-13% | 24% |
| Discontinuation | 4-7% | 4-7% |
Counter to what marketing implies, tirzepatide actually has a slightly better tolerability profile in most trials, possibly because GIP activation buffers some GI effects. Both drugs carry the same boxed warning about thyroid C-cell tumors and the same contraindications (personal/family history of medullary thyroid carcinoma, MEN2 syndrome).
Tirzepatide vs Semaglutide: Dosing Schedule
Both drugs require gradual titration over 16 to 20 weeks to minimize GI side effects.
| Week | Tirzepatide (Zepbound) | Semaglutide (Wegovy) |
|---|---|---|
| 1 to 4 | 2.5 mg | 0.25 mg |
| 5 to 8 | 5 mg | 0.5 mg |
| 9 to 12 | 7.5 mg | 1.0 mg |
| 13 to 16 | 10 mg | 1.7 mg |
| 17+ | 12.5 mg or 15 mg target | 2.4 mg target |
Both administered subcutaneously, once weekly, on the same day every week. Both can be injected in the abdomen, thigh, or upper arm. Storage: refrigerate unopened pens; once started, room temperature is fine for 21-28 days.
Tirzepatide vs Semaglutide: Cost
This is where most decisions actually get made.
| Path | Tirzepatide (Zepbound) | Semaglutide (Wegovy) |
|---|---|---|
| Brand cash retail | $1,060/mo | $1,350/mo |
| Brand with manufacturer card + insurance | $25-$200/mo | $25-$200/mo |
| LillyDirect / NovoCare cash program | $349-$499/mo | $499/mo |
| Compounded via telehealth | $258/mo | $146/mo |
Compounded tirzepatide and compounded semaglutide are the cheapest legitimate routes for cash-pay patients. They're dispensed by US-licensed 503A and 503B compounding pharmacies and prescribed by US-licensed clinicians via telehealth. They are not FDA-approved finished products but are legal.
Tirzepatide vs Semaglutide: Switching Between the Two
If you've been on semaglutide and want to switch to tirzepatide (or vice versa), the protocol depends on direction.
- Semaglutide to tirzepatide: typical washout is 1 week from last semaglutide dose. Restart tirzepatide at the 2.5 mg starter dose, NOT a "matching" higher dose. Yes, you'll lose two months to titration.
- Tirzepatide to semaglutide: 1 week washout, restart semaglutide at 0.25 mg. Same titration sequence.
- Insurance prior auth: most plans require a new prior authorization when switching. Have your prescriber document the reason (cost, side effects, switching coverage).
Do not skip the starter dose. The reason GLP-1s require titration isn't dose math; it's GI tolerance, which resets every time you stop the medication.
Tirzepatide vs Semaglutide: Cardiovascular and Other Benefits
Semaglutide has one important advantage: stronger cardiovascular evidence. The SELECT trial (2023) showed Wegovy reduced major adverse cardiovascular events (MACE) by 20% in patients with obesity and pre-existing cardiovascular disease. Tirzepatide's SURMOUNT-MMO cardiovascular outcomes trial is ongoing but doesn't yet have published outcomes.
For sleep apnea, NAFLD/NASH, and chronic kidney disease, both have positive trial signals. For pure weight loss, tirzepatide is the stronger pick. For cardiovascular protection in established disease, semaglutide currently has the data.
Who Should Pick Tirzepatide vs Semaglutide
| Patient Profile | Recommended | Why |
|---|---|---|
| Most weight loss possible, no other indication | Tirzepatide (Zepbound) | SURMOUNT-5 head-to-head wins |
| Established cardiovascular disease + obesity | Semaglutide (Wegovy) | SELECT trial proved MACE reduction |
| Insurance covers Wegovy not Zepbound (or vice versa) | Whichever is covered | Real-world cost beats marginal efficacy gap |
| Tried semaglutide, plateaued under 10% | Switch to tirzepatide | Dual mechanism may unlock more |
| Very GI-sensitive | Either, with slow titration | Profiles are similar; pace matters more than choice |
| T2D + obesity | Tirzepatide (Mounjaro/Zepbound) | Better A1C reduction in head-to-heads |
| Pregnancy planning within 2 months | Neither | Both contraindicated; stop both 2 months before |
The honest reality: for the dominant question of "which gets me more weight loss," tirzepatide vs semaglutide has a clear answer (tirzepatide). For everything else, individual factors matter more than the molecule.
How to Get Tirzepatide or Semaglutide
Three paths regardless of which you pick:
- Brand prescription via insurance. Best route if your plan covers Zepbound or Wegovy. Prior authorization is usually required, your doctor needs to document BMI ≥30 (or ≥27 with comorbidity).
- Brand cash via LillyDirect or NovoCare. Eli Lilly sells Zepbound vials direct at $349-$499/mo; Novo Nordisk's NovoCare offers Wegovy at $499/mo. Both require ID verification and a prescription.
- Compounded via telehealth. Compounded tirzepatide from $258/mo, compounded semaglutide from $146/mo. Yucca Health and MEDVi are the two providers our readers use most. Both use US compounding pharmacies and US-licensed clinicians.
Frequently Asked Questions
The Bottom Line on Tirzepatide vs Semaglutide
For pure weight loss in 2026, tirzepatide vs semaglutide has a clear winner: tirzepatide produces approximately 50% more weight loss at maximum doses (20.2% vs 13.7% per SURMOUNT-5). Side effects are comparable. Brand cash price is cheaper for tirzepatide. The compounded telehealth route makes either accessible at $146 to $258/mo.
Pick semaglutide if you have established cardiovascular disease (where SELECT trial data favors it), if your insurance covers only Wegovy, or if your prescriber recommends it based on your specific medical history. Pick tirzepatide otherwise.
For broader context, see our best GLP-1 for weight loss ranking, our cheapest GLP-1 cost analysis, our how telehealth GLP-1 works guide, our cheapest tirzepatide guide, and our compounded semaglutide guide.
Medical Disclaimer: This article is for informational purposes only and is not medical advice. GLP-1 medications including tirzepatide and semaglutide are prescription drugs that require evaluation by a licensed clinician. Always disclose your full medical history during intake, follow your prescribing clinician's titration schedule, and seek in-person care for severe side effects including persistent abdominal pain, signs of pancreatitis, or allergic reactions. Compounded GLP-1 medications are dispensed under FDA 503A and 503B oversight but are not FDA-approved finished products. This article contains affiliate links; we may earn a commission when you order through them, which keeps PeptideDeck free for readers.